Sangamo Therapeutics Inc at Bank of America Healthcare Conference Transcript
(technical difficulty) of the Bank of America Healthcare Conference. My name is Greg Harrison. I'm one of the biotech analysts here at BofA. I also have Mary Kate Davis from the team here with me. And it's my pleasure today to introduce Mark McClung, Executive Vice President and CEO of Sangamo Therapeutics.
Mark, would you like to give some opening remarks. And then after that, we can jump into the Q&A?
Yes, absolutely. So first of all, Greg, Mary Kate, thanks for having us, and thank you for your interest in Sangamo Therapeutics. So these are forward-looking statements. And as usual, we refer you to the quarterly filing that was put in last week, just for your reference.
So Sangamo Therapeutics is an exciting company. Actually, it's a genomics medicine company. It's got a long history in terms of being a pioneer in genomic medicines that hopefully will give you a sense of today. We've got multiple
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
